Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
October 30, 2023 08:30 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board
October 24, 2023 09:00 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel’s Hadassah Medical Center
September 14, 2023 08:30 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...
Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 28, 2023 16:02 ET
|
Alpha Tau Medical Ltd.
– Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April – – 89% CR, two-year local recurrence-free survival of 77%, and no...
Alpha Tau Medical to Participate in September Investor Conferences
August 24, 2023 08:00 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT
August 17, 2023 17:00 ET
|
Alpha Tau Medical Ltd.
- 81 lesions treated across four feasibility trials of head and neck or skin cancers demonstrated 89% complete response rate. - Two-year local recurrence-free survival rate of 77%. - The analysis...
Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023
August 02, 2023 09:00 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau Medical to Participate in June Investor Conferences
May 24, 2023 16:01 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, May 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 23, 2023 16:01 ET
|
Alpha Tau Medical Ltd.
- Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer, which began enrolling patients in March - - Treated the first patient with advanced inoperable pancreatic cancer in a...
Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University
May 17, 2023 16:30 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...